Skip to main content
banner image
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
1.Plasma Medicine, edited by M. Laroussi, M. Kong, G. Morfill, and W. Stolz ( Cambridge, 2012).
2. A. Fridman and G. Friedman, Plasma Medicine ( Wiley, 2013).
3. M. Keidar and I. I. Beilis, Plasma Engineering: Application in Aerospace, Nanotechnology and Bionanotechnology ( Elsevier, Oxford, UK, 2013).
4. G. E. Morfill, M. G. Kong, and J. L. Zimmermann, “ Focus on plasma medicine,” New J. Phys. 11, 115011 (2009).
5. M. Keidar, “ Plasma for cancer treatment,” Plasma Source Sci. Technol. 24, 033001 (2015).
6. G. Fridman, G. Friedman, A. Gutsol, A. B. Shekhter, V. N. Vasilets, and A. Fridman, “ Applied plasma medicine,” Plasma Processes Polym. 5, 503 (2008).
7. M. Vandamme, E. Robert, S. Pesnel, E. Barbosa, S. Dozias, J. Sobilo, S. Lerondel, A. Le Pape, and J. M. Pouvesle, “ Antitumor effect of plasma treatment on U87 glioma xenografts: Preliminary results,” Plasma Processes Polym. 7, 264 (2010).
8. M. Keidar, R. Walk, A. Shashurin, P. Srinivasan, A. Sandler, S. Dasgupta, R. Ravi, R. Guerrero-Preston, and B. Trink, “ Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy,” Br. J. Cancer 105, 1295 (2011).
9. M. Vandamme, E. Robert, S. Lerondel, V. Sarron, D. Ries, S. Dozias, J. Sobilo, D. Gosset, C. Kieda, B. Legrain, J.-M. Pouvesle, and A. Le Pape, “ ROS implication in a new antitumor strategy based on non-thermal plasma,” Int. J. Cancer 130, 2185 (2011).
10. E. A. Ratovitski, X. Cheng, D. Yan, J. H. Sherman, J. Canady, B. Trink, and M. Keidar, “ Anti-cancer therapies of 21st century: Novel approach to treat human cancers using cold atmospheric plasma,” Plasma Processes Polym. 11, 11281137 (2014).

Data & Media loading...


Article metrics loading...



Intense research effort over last few decades in low-temperature (or cold) atmospheric plasma application in bioengineering led to the foundation of a new scientific field, plasma medicine. Cold atmospheric plasmas (CAP) produce various chemically reactive species including reactive oxygen species (ROS) and reactive nitrogen species (RNS). It has been found that these reactive species play an important role in the interaction of CAP with prokaryotic and eukaryotic cells triggering various signaling pathways in cells.


Full text loading...


Access Key

  • FFree Content
  • OAOpen Access Content
  • SSubscribed Content
  • TFree Trial Content
752b84549af89a08dbdd7fdb8b9568b5 journal.articlezxybnytfddd